SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Nifty Pharma Companies

Sensex 77550.25
918.6 (1.20%)
Pharmaceuticals sector is one of the key sectors where Indian companies have created a global brand for themselves besides software. Indian companies have taken advantage of the opportunities in the regulated generics market in the western countries ... Pharmaceuticals sector is one of the key sectors where Indian companies have created a global brand for themselves besides software. Indian companies have taken advantage of the opportunities in the regulated generics market in the western countries and made deep inroads especially in providing low cost equivalents of expensive drugs. Pharma outsourcing into India and low cost Healthcare services are expected to be the key areas of growth in the near future. In addition, the inherent potential of biotechnology has also attracted many new companies and this is also a key growth area for Indian companies. NSE Indices has developed Nifty Pharma Index to capture the performance of the companies in this sector. Read More

See MoneyWorks4me's rating on Quality, Valuation, Price Trend and Overall Rating to take informed stock investing decisions. Decizen :- Q: Quality, V: Valuation, PT: Price Trend

Filter
Nifty Pharma companies as on Apr-2026 |  5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks
Filter
sort up
 sort down
Company Name
DeciZen
sort up
 sort down
CMP
sort up
 sort down
Price
Change (%)
sort up
 sort down
Market
Cap (Cr)
sort up
 sort down
52Week
High
sort up
 sort down
52Week
Low
sort up
 sort down
ROE(%)
sort up
 sort down
P/E
sort up
 sort down
P/BV
sort up
 sort down
EV/
EBITDA
sort up
 sort down
5Y Sales
Gr.(%)
sort up
 sort down
5Y Profit
Gr.(%)
1
Divis Laboratories Ltd
Q V PT
6,120 2.72% 1,62,454
Large Cap		 7,078
08 Jul, 25		 5,389
11 Apr, 25		 15.14 65.53 10.16 41.58 11.65 10.50
2
Piramal Pharma Ltd
Q V PT
146 2.24% 19,420
Small Cap		 228
23 Apr, 25		 133
23 Mar, 26		 9.79 27.14 2.47 15.74 0.00 0.00
3
Ajanta Pharma Ltd
Q V PT
2,804 1.95% 35,026
Small Cap		 3,158
13 Mar, 26		 2,335
30 Sep, 25		 24.45 34.52 7.63 23.62 12.43 17.07
4
JB Chemicals & Pharmaceuticals Ltd
Q V+ PT
2,004 1.69% 32,172
Small Cap		 2,195
20 Mar, 26		 1,495
06 May, 25		 20.17 44.23 8.24 27.93 17.81 19.45
5
Dr. Reddys Laboratories Ltd
Q V PT
1,232 1.62% 1,02,830
Mid Cap		 1,378
12 Jun, 25		 1,105
11 Apr, 25		 17.66 18.47 2.76 11.11 13.26 22.29
6
Lupin Ltd
Q V PT
2,333 1.59% 1,06,646
Mid Cap		 2,376
11 Mar, 26		 1,839
06 Aug, 25		 20.83 22.96 5.12 13.69 8.11 0.00
7
Torrent Pharmaceuticals Ltd
Q V+ PT
4,157 1.57% 1,40,702
Large Cap		 4,480
13 Mar, 26		 3,101
09 May, 25		 26.68 61.93 15.49 35.02 7.72 15.29
8
Zydus Lifesciences Ltd
Q V PT
915 1.47% 92,116
Mid Cap		 1,059
19 Sep, 25		 813
16 Apr, 25		 20.74 18.65 3.51 11.64 10.27 30.57
9
Laurus Labs Ltd
Q V+ PT
1,098 1.33% 59,271
Mid Cap		 1,141
07 Jan, 26		 570
11 Apr, 25		 7.37 70.28 11.72 34.32 14.42 4.11
10
Alkem Laboratories Ltd
Q V+ PT
5,440 1.32% 65,045
Mid Cap		 5,933
13 Jan, 26		 4,717
10 Jul, 25		 17.86 29.65 4.55 22.77 5.71 10.33
11
Mankind Pharma Ltd
Q V PT
2,079 1.20% 85,817
Mid Cap		 2,727
15 Jul, 25		 1,910
23 Mar, 26		 14.52 50.37 5.38 30.52 14.65 12.79
12
Biocon Ltd
Q V PT
349 0.82% 56,505
Mid Cap		 425
18 Nov, 25		 309
25 Apr, 25		 1.61 7635.79 2.09 105.95 2.44 -9.71
13
Aurobindo Pharma Ltd
Q V PT
1,350 0.78% 78,408
Mid Cap		 1,370
08 Apr, 26		 1,017
02 Sep, 25		 8.24 36.80 3.56 24.33 -3.95 -0.50
14
Cipla Ltd
Q V PT
1,230 0.44% 99,325
Large Cap		 1,672
23 Oct, 25		 1,166
02 Apr, 26		 17.79 21.85 2.96 13.17 9.97 30.14
15
Ipca Laboratories Ltd
Q V PT
1,456 0.43% 36,942
Mid Cap		 1,624
17 Mar, 26		 1,253
24 Oct, 25		 12.48 45.88 4.79 20.92 8.87 4.68
16
Abbott India Ltd
Q V PT
25,770 -0.11% 54,760
Mid Cap		 35,922
03 Jul, 25		 25,350
24 Mar, 26		 35.71 35.93 12.48 25.13 9.38 18.78
17
Glenmark Pharmaceuticals Ltd
Q V+ PT
2,163 -0.29% 61,037
Mid Cap		 2,297
11 Mar, 26		 1,337
17 Apr, 25		 15.43 57.31 6.11 12.73 4.60 14.41
18
Gland Pharma Ltd
Q V PT
1,740 -0.35% 28,665
Small Cap		 2,130
29 Jul, 25		 1,382
11 Apr, 25		 11.53 24.52 2.77 14.73 9.35 7.37
19
Wockhardt Ltd
Q V+ PT
1,344 -1.96% 21,840
Small Cap		 1,870
12 Jun, 25		 1,087
23 Mar, 26		 -1.15 992.72 4.72 41.83 1.15 0.00
20
Sun Pharmaceutical Industries Ltd
Q V PT
1,655 -3.65% 3,97,018
Large Cap		 1,851
02 May, 25		 1,547
26 Sep, 25		 16.60 36.37 4.89 19.85 9.87 23.50
Screens:
AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks
×
×

Nifty Pharma - Today's Top Gainers

Company Name CMP Price Change(%)
Divis Lab
6,119.502.72%
Piramal Pharma
146.102.24%
Ajanta Pharma
2,803.501.95%
JB Chem & Pharma
2,003.751.69%
Dr. Reddys Lab
1,2321.62%
View More

Nifty Pharma - Today's Top Losers

Company Name CMP Price Change(%)
Sun Pharma Inds.
1,654.70-3.65%
Wockhardt
1,344.05-1.96%
Gland Pharma
1,739.85-0.35%
Glenmark Pharma
2,162.90-0.29%
Abbott India
25,770.05-0.11%

News about Nifty Pharma

Track Now:

5 Star Companies Large Cap Companies Mid Cap Companies Small Cap Companies Nifty Microcap Companies Top IT Companies Tax saver funds Analyze your Equity Funds Nifty Index Funds

Trending Blogs

All Indices

Broad Based Indices:

Nifty 50 Nifty Next 50 Nifty 100 Nifty 200 Nifty Total Market Nifty 500 Nifty Midcap 150 Nifty Midcap 50 Nifty Midcap Select Nifty Midcap 100 Nifty Smallcap 250 Nifty Smallcap 50 NIFTY Smallcap 100 Nifty Microcap 250 Nifty Largemidcap 250 Nifty500 Multicap 50:25:25

Sectoral Indices:

Nifty Auto Nifty Bank Nifty Healthcare Nifty IT Nifty Financial Services Nifty Media Nifty Metal Nifty Pharma Nifty Private Bank Nifty PSU Bank Nifty Realty Nifty Consumer Durables Nifty Oil & Gas Nifty Financial Services 25/50 Nifty Financial Services Ex Bank Nifty FMCG

Thematic Indices:

Nifty Aditya Birla Group Nifty Core Housing Nifty Commodities Nifty CPSE Nifty Financial Services Nifty Energy Nifty Housing Nifty India Consumption Nifty India Defence Nifty India Digital Nifty India Manufacturing Nifty Infrastructure Nifty Mahindra Group Nifty Midcap Liquid 15 Nifty MNC Nifty Mobility Nifty PSE Nifty Non-cyclical Consumer Nifty Services Sector Nifty Shariah 25 Nifty Tata Group Nifty Tata Group 25% Cap Nifty Transportation & Logistics Nifty100 Liquid 15 Nifty50 Shariah Nifty500 Shariah NIFTY SME EMERGE Nifty100 Esg NIFTY100 Enhanced ESG Nifty100 ESG Sector Leaders

Strategy Indices:

Nifty100 Equal Weight Nifty100 Low Volatility 30 Nifty 50 Arbitrage Nifty200 Momentum 30 NIFTY100 Alpha 30 Nifty Alpha 50 Nifty Alpha Low-volatility 30 Nifty Alpha Quality Low-volatility 30 Nifty Alpha Quality Value Low-volatility 30 Nifty Growth Sectors 15 Nifty High Beta 50 NIFTY100 Quality 30 NIFTY Midcap150 Quality 50 Nifty Quality Low Volatility 30 Nifty50 Dividend Points Nifty50 Equal Weight Nifty50 Value 20 Nifty500 Value 50 Nifty200 Quality 30

Nifty Pharma Companies FAQs

Intro:

Pharmaceuticals sector is one of the key sectors where Indian companies have created a global brand for themselves besides software. Indian companies have taken advantage of the opportunities in the regulated generics market in the western countries and made deep inroads especially in providing low cost equivalents of expensive drugs. In addition, the inherent potential of biotechnology has also attracted many new companies and this is also a key growth area for Indian companies. NSE Indices has developed Nifty Pharma Index to capture the performance of the companies in this sector.

Statistics:

The Nifty Pharma has delivered a CAGR of ~10% over the last decade. Pharma outsourcing into India and low cost Healthcare services are expected to be the key areas of growth in the near future. India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies ~50% of the global demand for various vaccines, 40% of generic demand in the US and 25% of all medicines in the UK. Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025.

The Union Cabinet has given its nod for the amendment of existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100 per cent under the automatic route for manufacturing of medical devices subject to certain conditions.

The drugs and pharmaceuticals sector attracted cumulative FDI inflow worth US$ 16.50 billion between April 2000 and March 2020 according to the data released by Department for Promotion of Industry and Internal Trade (DPIIT).

Pharmaceuticals export from India stood at US$ 20.70 billion in FY20. Pharmaceutical export include bulk drugs, intermediates, drug formulations, biologicals, Ayush and herbal products and surgical.

India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected grow at an average growth rate of around 30 per cent a y-o-y to reach US$ 100 billion by 2025.

India's domestic pharmaceutical market turnover reached Rs 1.4 lakh crore (US$ 20.03 billion) in 2019, up 9.8% from Rs 129,015 crore (US$ 18.12 billion) in 2018.

Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.

Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers, which are on the rise.

The steps taken by the government to reduce costs and bring down healthcare expenses drives the revenues of the pharma companies. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies. Low manufacturing cost is the key advantage of Indian players and this drives their growth and profitability.

Pharma sector includes active pharmaceutical ingredients (API) industry which is a part of chemical industry. The API which happens to be the raw material used by pharma companies is manufactured by companies with speciality in chemical segments. Hence they are crucial part of the pharma chain. The sector comprises of the multiple companies specialized in generic drugs and having low manufacturing as their key advantage. Also there are some large size companies which are specialized in over-the counter drugs/ medical accessories (like inhaler by Cipla). Some companies aim for the mass market while some aim for the niche drugs.

The large size companies such as Cipla, Lupin, Sun Pharma own notable brands, have a distribution across the country, capacity to heavily spend on R&D due to their balance sheet size. Pharma companies tend to trade at premium valuations due to their defensive nature of business. The other ancillary companies are packaging companies and other contract manufacturing companies.

1. Sun Pharma
Established in 1983 by Mr. Dilip Shanghvi, Sun Pharma (SUN) is the Indian MNC that manufactures and sells pharmaceutical formulations and APIs primarily in India and the United States. Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States.
The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anti-cancers, steroids, peptides and controlled substances.
The 2014 acquisition of Ranbaxy made Sun the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest speciality generic company globally.

Sun Pharma Growth Parameters


2. Cipla
Founded by Khwaja Abdul Hamied in 1935, Cipla Limited is an Indian MNC, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions. Cipla is the key player in OTC medical accessories like inhaler pump.

Cipla Ltd Growth Parameters

3. Lupin
Incorporated in the year 1968 by Desh Bandhu Gupta, Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, India. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. Lupin's research program covers the entire pharma product chain like generic research, Advanced Drug Delivery Systems, Intellectual Property Management, Novel Drug Discovery and Development and Biotechnology Research.

Lupin Ltd Growth Parameters

There is no specific index fund or ETF that can give you an exposure to all the Pharma companies. One idea is to buy stocks in the Nifty Pharma index in proportion to their weights in the index. Another idea is to gain exposure via investing in funds like DSP Healthcare, Mirae Asset Healthcare, etc.

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA ROE
Abbott India Ltd. (M) Very Good 25,770 54,760 35.93 12.48 25.13 35.71
Torrent Pharmaceuticals Ltd. (L) Very Good 4,157 1,40,702 61.93 15.49 35.02 26.68
Ajanta Pharma Ltd. (S) Very Good 2,804 35,026 34.52 7.63 23.62 24.45
Lupin Ltd. (M) Somewhat Good 2,333 1,06,646 22.96 5.12 13.69 20.83
Zydus Lifesciences Ltd. (M) Very Good 915 92,116 18.65 3.51 11.64 20.74

Based on the past year's gain, the best performing stocks are:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) Yearly gain (%)
Laurus Labs Ltd. (M) Very Good 1,098 59,271 94.87
Glenmark Pharmaceuticals Ltd. (M) Very Good 2,163 61,037 57.09
Torrent Pharmaceuticals Ltd. (L) Very Good 4,157 1,40,702 32.97
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 2,004 32,172 29.98
Aurobindo Pharma Ltd. (M) Very Good 1,350 78,408 27.78
View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA 5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 2,004 32,172 44.23 8.24 27.93 17.81
Mankind Pharma Ltd. (M) Very Good 2,079 85,817 50.37 5.38 30.52 14.65
Laurus Labs Ltd. (M) Very Good 1,098 59,271 70.28 11.72 34.32 14.42
Dr. Reddys Laboratories Ltd. (M) Very Good 1,232 1,02,830 18.47 2.76 11.11 13.26
Ajanta Pharma Ltd. (S) Very Good 2,804 35,026 34.52 7.63 23.62 12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA 5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M) Very Good 915 92,116 18.65 3.51 11.64 30.57
Cipla Ltd. (L) Very Good 1,230 99,325 21.85 2.96 13.17 30.14
Sun Pharmaceutical Industries Ltd. (L) Very Good 1,655 3,97,018 36.37 4.89 19.85 23.50
Dr. Reddys Laboratories Ltd. (M) Very Good 1,232 1,02,830 18.47 2.76 11.11 22.29
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 2,004 32,172 44.23 8.24 27.93 19.45

MoneyWorks4me can help you identify the best performing Pharma sector stocks. The decision maker allows for simple and effective analysis.

Decision Maker

Sign up now to start a successful investing journey!

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×